Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Sotera Health (SHC)

Sotera Health adds Richard G. Kyle, former Timken CEO, to board as director

Neutral Impact 2 of 5 leadership Written later

Sotera Health expanded its board from eleven to twelve directors and appointed Richard G. Kyle as a Class III director, effective immediately, on February 4, 2026. Kyle previously served as president and CEO of The Timken Company from May 2014 to September 2024, and the filing describes him as independent under Nasdaq rules. The change adds an experienced industrial executive to the board and is a governance update rather than a financial result.

Key points

  • Board increased from eleven to twelve directors; Richard G. Kyle appointed Class III director effective February 4, 2026
  • Kyle to serve on the Leadership Development and Compensation Committee and the Nominating and Corporate Governance Committee
  • Kyle was President and CEO of The Timken Company from May 2014 to September 2024
  • Kyle receives standard non-employee director pay, including an annual cash retainer and annual restricted stock unit grant

The filing

CompanySotera Health (SHC)
Form8-K, current report
Filed with the SECFeb 5, 2026, 7:35 AM ET
Accession number0001822479-26-000007

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:00 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.